Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association Congress
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association Congress
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors at 2026 American Society of Clinical Oncology Annual Meeting
Cogent Biosciences Announces FDA Acceptance of New Drug Application with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association 2026 Congress
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors at the 2026 American Society of Clinical Oncology Annual Meeting
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research Annual Meeting 2026
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Steadright Removes Titanbeach One Technical Report And Retains Qualified Geologist For New Technical Report
The Metal You've Never Heard Of Is Becoming a National-Security Priority -- and America Barely Mines It
